FDA expands approval of Moderna's RSV vaccine to some adults under age 60

The U.S. Food and Drug Administration expanded its approval of Moderna's respiratory syncytial virus (RSV) vaccine on Thursday to include adults under the age of 60 at increased risk of the disease.

Previously, the vaccine, known as mRESVIA, had been licensed for use for those aged 60 and older.

Approval for mRESVIA came after Moderna conducted a late-stage clinical trial showing the vaccine helped boost immune responses in younger adults...